What Is the Best Cream for Lichen Sclerosus?

Clobetasol propionate 0.05% ointment is the best-studied and most widely recommended cream (technically, ointment) for lichen sclerosus. It is classified as an ultrapotent topical corticosteroid and has been the first-line treatment for genital lichen sclerosus for decades, with research consistently showing that it brings symptom relief to the large majority of patients. But the question of “best cream” turns out to be more layered than a single product name, because the formulation matters, the steroid potency class matters, and what you use after the initial treatment phase matters just as much as what you start with.

Why Clobetasol Propionate Is the Standard

Clobetasol propionate sits at the top of the corticosteroid potency scale. For a condition driven by chronic inflammation and progressive scarring, that potency is the point. In one of the earlier trials establishing its use, about three-quarters of patients achieved complete remission of symptoms, and just under half saw visible improvement in the clinical appearance of affected skin.¹ A longer-term study following patients for years found that itching typically resolved within the first three months of treatment, with complete remission rates climbing over time. Younger patients tended to respond faster and more completely: estimated complete remission at three years was much higher in patients under 50 than in those over 70.²

The typical initial regimen involves applying the steroid once daily (or sometimes twice daily) for roughly 12 weeks, then tapering the frequency. That 12-week induction period appears consistently across clinical guidelines as the recommended starting course.³ Patients who expect overnight results will be disappointed, but most notice significant itch relief within the first few weeks.

Ointment, Not Cream

Here is a detail that matters more than most patients realize: the vehicle the steroid comes in changes the experience considerably. Clobetasol is available as both a cream and an ointment. For lichen sclerosus, the ointment is preferred. Ointments are oil-based, which means they stay on the skin longer and deliver more of the active ingredient. Creams are water-based and absorb quickly, which sounds appealing, but they often contain preservatives and alcohols that can cause burning and stinging on already inflamed or fissured skin. A scoping review of treatment options explicitly recommended ointments over creams as first-line therapy for this reason.⁴

This distinction has been tested directly. When researchers compared mometasone furoate ointment against mometasone furoate cream in patients with vulvar lichen sclerosus, the ointment produced a significantly higher improvement in symptom scores. The responder rate was also higher in the ointment group.⁵ So when your doctor writes a prescription, it is worth confirming you are getting the ointment formulation, not the cream. The greasier feel is a tradeoff most patients adjust to quickly.

Mometasone Furoate as an Alternative Steroid

Clobetasol is not the only corticosteroid that works. Mometasone furoate 0.1% sits one tier below clobetasol in potency (it is classified as “potent” rather than “ultrapotent”), and head-to-head trials have found it performs comparably. In one randomized trial, both clobetasol and mometasone achieved an 89% responder rate after 12 weeks, with no significant differences in any efficacy measure.⁶ A separate trial confirmed similar results over a 12-month observation period, finding roughly three-quarters of patients in both groups were classified as responders. The mometasone group actually showed faster itch improvement at the three-month mark.⁷

Why does this matter? Because some clinicians and patients worry about the side-effect profile of the very strongest steroids, even though those worries are largely unfounded in this context (more on that below). Having a potent steroid that matches clobetasol’s results gives doctors a second option when patients are anxious about using an ultrapotent product long-term or when pharmacy availability is a problem.

What About Non-Steroidal Creams?

Two calcineurin inhibitors, tacrolimus and pimecrolimus, are the most-studied non-steroidal alternatives. These are immunomodulators that calm the immune response in the skin without thinning it the way steroids theoretically can. They are generally considered second-line, meaning they are tried when steroids do not work well enough or when there is a specific reason to avoid steroids.

A systematic review of tacrolimus for lichen sclerosus found that about 90% of treated patients showed clinical improvement, with side effects severe enough to stop treatment occurring in only about 1% of cases. The review also reported that tacrolimus was associated with better patient-reported outcomes and clinician-rated improvement compared to corticosteroids in some study comparisons.⁸ Those results sound striking, but the evidence base for tacrolimus in lichen sclerosus is much smaller and less rigorous than for clobetasol, which makes direct superiority claims premature. Most guidelines still position calcineurin inhibitors as alternatives rather than replacements.

Pimecrolimus 1% cream has also shown encouraging results. In one study of postmenopausal women, most patients improved, and about two-thirds achieved complete remission after three months. However, older patients and those with more advanced disease responded poorly, and some patients who initially cleared experienced relapses during follow-up.⁹ A head-to-head randomized trial comparing clobetasol with pimecrolimus found that both improved itching and burning, though neither was statistically superior for those symptoms.¹⁰ The European guideline for lichen sclerosus treatment lists calcineurin inhibitors as second-line therapy.¹¹

Tretinoin as a Niche Option

Topical tretinoin (a retinoid, essentially a vitamin A derivative) has been investigated in small studies for vulvar lichen sclerosus. One trial found that tretinoin 0.025% cream applied over 24 weeks significantly improved itching, skin pallor, and thickened patches, with researchers concluding it could be a useful alternative to corticosteroids, particularly for the hyperkeratotic (thickened, scaly) features of the disease.¹² However, when tretinoin was combined with mometasone furoate to see if the duo outperformed the steroid alone, the combination did not enhance results. The study authors suggested that the retinoid’s irritation potential may have offset any added benefit.¹³ Tretinoin is not a mainstream option, but it occasionally appears in the toolkit for patients who cannot tolerate steroids or calcineurin inhibitors.

Emollients and Barrier Care

Every treatment guideline for lichen sclerosus includes the unglamorous but important recommendation to use emollients alongside your prescribed treatment. The European guideline explicitly recommends co-treatment with emollients for all patients.¹¹ A plain, fragrance-free barrier cream or ointment (petroleum jelly is a simple and effective option) can protect fragile skin from friction, moisture, and irritants. Since lichen sclerosus skin is easily damaged and prone to contact irritation, avoiding products with fragrances, dyes, or common sensitizers is just as important as applying the right prescription cream. Many patients find that liberal use of a barrier ointment between steroid applications significantly improves day-to-day comfort.

Safety Concerns Are Mostly Overblown

The single biggest barrier to effective treatment is patients being afraid of using a potent steroid on genital skin. The fear makes intuitive sense: steroid-thinned skin sounds terrifying in an area that is already fragile. But the evidence consistently shows that clobetasol, when used as directed for lichen sclerosus, does not cause the thinning, stretch marks, or other side effects people associate with long-term steroid misuse. One early study specifically looked for skin atrophy and infection during clobetasol treatment and found neither.¹⁴ This finding has been replicated many times since. In practice, lichen sclerosus itself causes thinning and scarring if undertreated, so the risk of not using steroids is substantially higher than the risk of using them. If you are rationing your applications or skipping days because of steroid anxiety, you are likely making the condition worse.

The Maintenance Phase

Lichen sclerosus is, in most people, a lifelong condition that waxes and wanes. The initial 12-week treatment phase is just the beginning. After symptoms are controlled, you need some kind of ongoing strategy to prevent flares. Three broad approaches exist for maintenance: using the steroid only when symptoms return (“reactive”), using it on a fixed low-frequency schedule regardless of symptoms (“proactive”), or using it on a continuous but reduced-dose schedule.³

The proactive approach has the strongest evidence behind it. A randomized study found that applying mometasone furoate ointment just twice a week after remission was effective and safe for maintaining control over nearly a year and preventing relapses.¹⁵ This twice-weekly schedule is much less burdensome than daily application, and most patients can sustain it long-term. For male patients, a retrospective study found that both a milder steroid (methylprednisolone aceponate) and tacrolimus ointment worked equally well for maintenance after initial clobetasol treatment.¹⁶

Why Treating Matters Beyond Symptoms

Lichen sclerosus carries a small but real risk of progressing to vulvar squamous cell carcinoma. This is one of the stronger arguments for consistent, long-term treatment even when symptoms feel manageable. A study of patients with both lichen sclerosus and a history of vulvar cancer found that those who adhered to topical corticosteroid therapy had a cancer recurrence rate of about 27%, compared with historical rates of 44-47% in less compliant groups. The researchers proposed that by controlling chronic inflammation, steroids reduce the environment that promotes cancer development.¹⁷ This is not proof that steroids prevent cancer outright, but it is the kind of evidence that makes consistent treatment harder to dismiss.

Lichen Sclerosus in Children

Parents are understandably nervous about applying potent steroids to a child’s genital skin. The good news is that pediatric lichen sclerosus generally responds very well to the same treatment used in adults, and children appear to tolerate it with minimal side effects. A large referral-center study of pediatric patients found that symptom remission was achieved in 83% of cases after a standard induction regimen. Itching dropped from 80% of patients at baseline to 13% after treatment, and burning fell from 36% to 8%. Side effects were mild, self-limiting, and reported in only 8% at the first follow-up and 1% at the second. No serious adverse events occurred.¹⁸

An earlier study followed children over periods ranging from six months to three years and similarly found that all patients improved with ultrapotent steroid treatment. Recurrences happened, but they were mild and responded quickly to brief reapplication, often just a few days’ worth. No steroid-induced thinning or visible blood vessel changes were found on follow-up exams.¹⁹ A subset of children may eventually outgrow the condition or at least experience prolonged remission through puberty, which is not common in adults.

How Treatment Differs for Men

Male lichen sclerosus (historically called balanitis xerotica obliterans) most commonly affects the foreskin and glans. Topical clobetasol is still the first-line treatment, but the role of surgery is more prominent than in women. Circumcision can be curative for men whose disease is confined to the foreskin. A systematic review found that topical steroids avoided the need for circumcision in about 35% of boys treated.²⁰ That means steroids are worth trying first, but a substantial majority still ended up needing surgery. In circumcised men who continue to have disease on the glans, quality-of-life data suggest that ongoing topical therapy still helps, though circumcised patients who no longer need active treatment report better overall quality of life than those still managing with creams alone.²¹

Sexual Function Improves, but Often Not Enough

Lichen sclerosus can profoundly affect sexual function, and this is one area where treatment helps but rarely solves the problem entirely. In a study of women before and after treatment with either clobetasol or pimecrolimus, sexual distress scores improved significantly in both groups. The clobetasol group’s average distress score roughly halved, dropping from 29 to 15. But even after treatment, the average scores still indicated clinically meaningful sexual dysfunction.²² A retrospective cohort found that among women who were sexually inactive because of pain at the start of treatment, about 37% became sexually active again after steroid therapy.²³ These numbers tell a real but incomplete story: steroid treatment reduces pain and improves function for many, yet the scarring and architectural changes that lichen sclerosus causes to the vulva are not fully reversible with creams. For patients dealing with persistent sexual difficulties, pelvic floor physical therapy and dilator use often complement topical treatment.

Emerging Treatments on the Horizon

For the minority of patients whose disease does not respond adequately to any available topical treatment, the research landscape is slowly expanding. Platelet-rich plasma (PRP) and adipose-derived stem cell therapies have been used in refractory cases at specialist centers, reportedly with good results and no major side effects.²⁴ These are procedural treatments rather than creams, and they remain experimental.

On the pharmaceutical side, JAK inhibitors are attracting interest. A case report described a 62-year-old woman with widespread lichen sclerosus that had failed multiple conventional treatments. After starting the oral JAK1 inhibitor upadacitinib, her itching improved significantly over 10 months, and her sclerotic skin patches showed marked improvement without serious side effects.²⁵ A single case report is about as preliminary as evidence gets, but JAK inhibitors have transformed treatment in several other inflammatory skin conditions, and trials in lichen sclerosus are the logical next step. Topical JAK inhibitors already exist for conditions like eczema, and if they prove effective for lichen sclerosus, they could eventually offer a targeted non-steroidal option that works differently from calcineurin inhibitors.

For now, though, the practical answer for most patients remains straightforward: clobetasol propionate or mometasone furoate ointment for the initial treatment phase, a proactive twice-weekly maintenance schedule once things are under control, a plain emollient as daily protection, and a specialist who understands that this condition rarely goes away on its own.